EMEA-000520-PIP01-08-M05

Key facts

Invented name
Benlysta
Active substance
belimumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0183/2016
PIP number
EMEA-000520-PIP01-08-M05
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of systemic lupus erythematosus
Route(s) of administration
Intravenous use
Contact for public enquiries
Glaxo Group Limited

E-mail: eu.paediatrics-plans@gsk.com
Tel. +44 (0)20 8990 2458

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating